PMID- 26502751
OWN - NLM
STAT- MEDLINE
DCOM- 20160826
LR  - 20220317
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 5
DP  - 2015 Nov
TI  - Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer 
      via Akt and mitogen‑activated protein kinase kinase signaling pathways.
PG  - 6745-51
AB  - Breast cancer is the most common cause of female cancer-associated mortality. 
      Although treatment options, including chemotherapy, radiotherapy and surgery have 
      led to a decline in the mortality rates associated with breast cancer, drug 
      resistance remains one of the predominant causes for poor prognosis and high 
      recurrence rates. The present study investigated the potential effects of the 
      natural product, isorhamnetin on breast cancer, and examined the effects of 
      isorhamnetin on the Akt/mammalian target of rapamycin (mTOR) and the 
      mitogen-activated protein kinase (MAPK)/MAPK kinase (MEK) signaling cascades, 
      which are two important signaling pathways for endocrine therapy resistance in 
      breast cancer. The results of the present study indicate that isorhamnetin 
      inhibits cell proliferation and induces cell apoptosis. In addition, isorhamnetin 
      was observed to inhibit the Akt/mTOR and the MEK/extracellular signal-regulated 
      kinase phosphorylation cascades. The inhibition of these two signaling pathways 
      was attenuated by the two Akt and MEK1 inhibitors, but not by the nuclear 
      factor-kappaB inhibitor. Furthermore, epidermal growth factor inhibited the effects 
      of isorhamnetin via activation of the Akt and MEK signaling pathways. These 
      results indicate that isorhamnetin exhibits antitumor effects in breast cancer, 
      which are mediated by the Akt and MEK signaling pathways.
FAU - Hu, Shan
AU  - Hu S
FAU - Huang, Liming
AU  - Huang L
FAU - Meng, Liwei
AU  - Meng L
FAU - Sun, He
AU  - Sun H
FAU - Zhang, Wei
AU  - Zhang W
FAU - Xu, Yingchun
AU  - Xu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NF-kappa B)
RN  - 07X3IB4R4Z (3-methylquercetin)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Breast Neoplasms/*drug therapy/enzymology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Cell Survival/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Epidermal Growth Factor/physiology
MH  - Female
MH  - Humans
MH  - MAP Kinase Signaling System
MH  - NF-kappa B/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Quercetin/*analogs & derivatives/pharmacology
PMC - PMC4626180
EDAT- 2015/10/28 06:00
MHDA- 2016/08/27 06:00
PMCR- 2015/08/28
CRDT- 2015/10/28 06:00
PHST- 2014/11/12 00:00 [received]
PHST- 2015/08/04 00:00 [accepted]
PHST- 2015/10/28 06:00 [entrez]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2016/08/27 06:00 [medline]
PHST- 2015/08/28 00:00 [pmc-release]
AID - mmr-12-05-6745 [pii]
AID - 10.3892/mmr.2015.4269 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Nov;12(5):6745-51. doi: 10.3892/mmr.2015.4269.